Polymorphs of n-malonyl-bis(n`-methyl-n`-thiobenzoylhydrazide)
AssigneeSynta Pharmaceuticals Corp.
InventorsElena Kostik, Lijun Sun, Joanna Dziewiszek, Jun Y. Choi
Life of this patent
Estimating the term…
Abstract
At least 70% by weight of Compound 1 is the single crystalline form, Form A, Form C, or Form D, of the compound. A pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent, and compound 1, wherein at least 70% by weight of the compound is the single crystalline form, Form A, Form C, or Form D, of the compound. A method of treating a subject with cancer comprises administering to the subject an effective amount of compound 1 or the pharmaceutical composition.
Claims19
A method of treating a subject with cancer, the method comprising administering to the subject an effective amount of a compound represented by the following Structural Formula:
- wherein at least 70% by weight of the compound is crystal habit 2 of a single crystalline form Form A of the compound;
- and
- wherein the crystal habit 2 of the single crystalline form Form A of the compound is characterized by at least one, two or three major X-ray powder diffraction peaks at 2θ angle selected from the group consisting of 10.76°, 14.49° and 16.33°.
86-88. (canceled)
A method of treating a subject with cancer, the method comprising administering to the subject an effective amount of a compound represented by the following Structural Formula:
- wherein at least 70% by weight of the compound is a single crystalline form of Form C of the compound;
- and
- wherein the single crystalline form Form C is characterized by at least one, two, three, four or five major X-ray powder diffraction peaks at 2θ angles selected from the group consisting of 10.32°, 14.80°, 21.49°, 23.05° and 30.12°.
A method of treating a subject with cancer, the method comprising administering to the subject an effective amount of a compound represented by the following Structural Formula:
- wherein at least 70% by weight of the compound is a single crystalline form of Form D of the compound;
- and
- wherein the single crystalline form Form D is characterized by at least one, three, five, seven, nine or eleven major X-ray powder diffraction peaks at 2θ angle selected from the group consisting of 7.52°, 13.22°, 13.90°, 17.23°, 22.06°, 22.66°, 23.35°, 24.97°, 26.65°, 28.44° and 29.19°.
Dependencies are inferred from the claim text.